Molecular markers help characterize neuroendocrine lung tumors

Annals of Thoracic Surgery

Volumn 62, Issue 3, 1996, Pages 798-810

  Rusch, Valerie W ^a   Klimstra, David S ^a   Venkatraman, Ennapadam S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

EID: 0030245718     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(96)00435-3     Document Type: Article

References (36)

1. 1. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972;64:413-21.
2. 2. Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. II. Well-differentiated neuroendocrine carcinomas. Ultrastruct Pathol 1984;7:185-99.
3. 3. Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmoary neuroendocrine neoplasms. I. Carcinoids. Ultrastruct Pathol 1984;6:15-27.
4. 4. DeCaro LF, Paladugu R, Benfield JR, Lovisatti L, Pak H, Teplitz RL. Typical and atypical carcinoids within the pulmonary APUD tumor spectrum. J Thorac Cardiovasc Surg 1983;86:528-36.
5. 5. Paladugu RR, Benfield JR, Pak HY, Ross RK, Teplitz RL. Bronchopulmonary Kulchitzky cell carcinomas. A new classification scheme for typical and atypical carcinoids. Cancer 1985;55:1303-11.
6. 6. Travis WD, Linnoila I, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-33.
7. 7. Hirsch FR, Matthews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988;62:973-7.
8. 8. Radice PA, Matthews MJ, Ihde DC, et al. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer 1982;50:2894-902.
9. 9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. 10. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Statist Soc 1972;135:185-206.
11. 11. Yousem SA. Pulmonary carcinoid tumors and well-differentiated neuroendocrine carcinomas. Is there room for an atypical carcinoid? Am J Clin Pathol 1991;95:763-4.
12. 12. Okike N, Bernatz PE, Woolner LB. Carcinoid tumors of the lung. Ann Thorac Surg 1976;22:270-7.
13. 13. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg 1985;89:8-17.
14. 14. Rea F, Binda R, Spreafico G, et al. Bronchial carcinoids: a review of 60 patients. Ann Thorac Surg 1989;47:412-4.
15. 15. Harpole Jr DH, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992;54:50-5.
16. 16. Ribet M, Gosselin B, Gambiez L, Frere LE. Bronchial carcinoids. Eur J Cardiothorac Surg 1993;7:347-50.
17. 17. Todd TR, Cooper JD, Weissberg D, Delarue NC, Pearson FG. Bronchial carcinoid tumors. Twenty years' experience. J Thorac Cardiovasc Surg 1980;79:532-6.
18. 18. Lequaglie C, Patriarca C, Cataldo I, Muscolino G, Preda F, Ravasi G. Prognosis of resected well-differentiated neuroendocrine carcinoma of the lung. Chest 1991;100:1053-6.
19. 19. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 1985;89:819-25.
20. 20. Warren WH, Memoli VA, Jordan AG, Gould VE. Reevaluation of pulmonary neoplasms resected as small cell carcinomas. Significance of distinguishing between well-differentiated and small cell neuroendocrine carcinomas. Cancer 1990;65:1003-10.
21. 21. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994;106(Suppl):367S-71S.
22. 22. Hirsch FR, Osterlind K, Hansen HH. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer 1983;52:2144-50.
23. 23. Fushimi H, Kikui M, Morino H, et al. Detection of large cell component in small cell lung carcinoma by combined cytologic and histologic examinations and its clinical implication. Cancer 1992;70:599-605.
24. 24. Jackson-York GL, Davis BH, Warren WH, Gould VE, Memoli VA. Flow cytometric DNA content analysis in neuroendocrine carcinoma of the lung. Correlation with survival and histologic subtype. Cancer 1991;68:374-9.
25. 25. Yousem SA, Taylor SR. Typical and atypical carcinoid tumors of lung: a clinicopathologic and DNA analysis of 20 tumors. Mod Pathol 1990;3:502-7.
26. 26. Chiba M, Takahashi TA, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990;5:1603-10.
27. 27. Rusch VW, Dmitrovsky E. Molecular biologic features of non-small cell lung cancer. Clinical implications. Chest Surg Clin N Am 1995;5:39-55.
28. 28. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665s-9s.
29. 29. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene 1993;8:1913-9.
30. 30. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-72.
31. 31. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85.
32. 32. Carbone DP, Mitsudomi T, Chiba I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106 (suppl):377S-81S.
33. 33. Lohmann DR, Fesseler B, Pütz B, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801.
34. 34. Roncalli M, Doglioni C, Springall DR, et al. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications. Diagn Mol Pathol 1992;1:129-35.
35. 35. Barbareschi M, Girlando S, Mauri FA, et al. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 1992; 166:343-50.
36. 36. Martini N, Zaman MB, Bains MS, et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg 1994;107:1-7.